Our findings suggest that ICAM‐1 activates platelets and promotes vascular permeability in TAECs through VE‐cadherin after insufficient RFA, and anti‐platelet and anti‐ICAM‐1 therapy could be used to prevent the progression of HCC after insufficient RFA. This evidence concerns the gene ICAM1 and hepatocellular carcinoma.